Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Program data pending ClinicalTrials.gov matching
· Last scored 2026-03-15
83.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (3)
Quick Facts: Minaris Advanced Therapies
- Signal Score
- 83.5/100 (as of 2026-03-15)
- Quality Compliance
- 100.0/100 — No FDA inspection records found for this manufacturer
- Headquarters
- Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
- Modalities
- CAR-T, Cell Therapy
- Active CGT Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CGT manufacturing intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
100.0
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Source: FDA Data Dashboard
No FDA inspection records found for this manufacturer · Quality score requires FDA inspection data
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
68.0
Parent company: Altaris Capital Partners
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of Altaris
SEC FilingsParent: Altaris
Parent company: Altaris Capital Partners
Financial assessment: 68.0/100
Capacity
70.0
Multi-site operations (4 CGT sites)
Sites: Philadelphia, PA, Allendale, NJ, Yokohama, Japan, Munich, Germany
Source: SEC EDGAR, press monitoring, company profiles
4 CGT manufacturing sites
StatusLimited
Multi-site operations (4 CGT sites)
Sites: Philadelphia, PA, Allendale, NJ, Yokohama, Japan, Munich, Germany
Recent Press3 articles
Multi-site operations (4 CGT sites)
Recent News 3 articles
12.5x Titer Boost Accelerates CAR-T Program To IND Filing - Bioprocess Online
12.5x Titer Boost Accelerates CAR-T Program To IND Filing Bioprocess Online
Minaris Unveils GMP-Grade NGS to Redefine Viral Safety Testing for Biologics and Advanced Therapies - BioBuzz
Minaris Unveils GMP-Grade NGS to Redefine Viral Safety Testing for Biologics and Advanced Therapies BioBuzz
J&J Plans $1B Investment in PA Cell Therapy Manufacturing Facility - BioSpace
J&J Plans $1B Investment in PA Cell Therapy Manufacturing Facility BioSpace
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: